ALKERMES, INC. for ALKERMES, INC.
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Confronting the opioid and mental illness epidemic HR 2872, Opioid Addiction and Modernization Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROBERT FORMAN | — |
| PETER NORMAN | — |
Medicare/Medicaid MMM
Maintain the program's six protected classes with respect to depression and schizophrenia S. 648, Medicare Formulary Improvement Act of 2015
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROBERT FORMAN | — |
| PETER NORMAN | — |
Pharmacy PHA
Ensure regulatory certainty for clinical trials and subsequent scheduling of FDA-approved medicines deemed to be controlled substances. HR 639/S 481, Improving Regulatory Transparency Act for New Medical Therapies Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROBERT FORMAN | — |
| PETER NORMAN | — |
Alcohol and Drug Abuse ALC
Advance the use of FDA-approved medicines to treat addiction in criminal justice and public health settings S. 524/HR 954 Comprehensive Addiction and Recovery Act S. 1695/HR 3420 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2016 (opioid funding) S.1695/HR 2578 Commerce, Justice, Science and Related Agencies Appropriations Act of 2016 (Bureau of Prisons medication pilot, inclusion of medications in Byrne Jag) HR 2029 The Military Construction and Veterans Affairs and Related Agencies Appropriations Act, 2016 (Opioid Medication Funding, Bureau of Prisons medication pilot, inclusion of medications in Byrne Jag)
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROBERT FORMAN | — |
| PETER NORMAN | — |
| DAVID TREWOLLA | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.